Dosing and Administration

Self-administered, subcutaneous Ig Hizentra lets you plan treatment around your patient's life

Patients with CIDP or PI can fit Hizentra into their normal routine

Administration volumes and rates for Hizentra (as tolerated)

Infusion parameters 1st infusion Subsequent infusions
CIDP – weekly
Volume (mL/site) ≤20 ≤50
Rate (mL/hr/site) ≤20 ≤50
PI – daily up to every 2 weeks
Volume (mL/site) ≤15 ≤25
Rate (mL/hr/site) ≤15 ≤25

Hizentra is indicated for the treatment of primary immune deficiency (PI) in adults and pediatric patients 2 years and older, and for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.

Convenient dosing and self-administration

Your patients are all different and deserve a treatment with the flexibility to fit their individual needs and preferences. Use the guidelines and dosing calculator for CIDP and PI below to initiate a patient's Hizentra therapy. Monitor the patient’s clinical response and adjust the duration of therapy based on patient need.

Vial sizes


  • In the PATH Study, subjects achieved sustained trough levels over a period of 24 weeks when receiving weekly doses
  • Initiate therapy with Hizentra 1 week after the last IVIg infusion
  • The recommended subcutaneous dose is 0.2 g/kg (1 mL/kg) body weight per week, administered in 1 or 2 sessions over 1 or 2 consecutive days
    • In the clinical study after transitioning from IVIg to Hizentra treatment, a dose of 0.4 g/kg (2 mL/kg) body weight per week was also safe and effective to prevent CIDP relapse
  • If CIDP symptoms worsen, consider reinitiating treatment with an IVIg approved for the treatment of CIDP, while discontinuing Hizentra
    • If improvement and stabilization are observed during IVIg treatment, consider reinitiating Hizentra at the dose of 0.4 g/kg body weight per week, administered in 2 sessions per week over 1 or 2 consecutive days, while discontinuing IVIg
    • If CIDP symptoms worsen on the 0.4 g/kg body weight per week dose, consider reinitiating therapy with an IVIg product approved for treatment of CIDP, while discontinuing Hizentra
  • Monitor the patient's clinical response and adjust the duration of therapy based on patient need
  • Hizentra may be infused in multiple injection sites depending on the volume


  • Before switching to Hizentra, obtain the patient's serum IgG trough level to guide subsequent dose adjustments
  • Weekly: Start Hizentra 1 week after last Intravenous Immune Globulin (Human) (IVIg) infusion. Initial weekly dose = (Previous IVIg dose (in grams) / No. of weeks between IVIg doses) X 1.37
  • Biweekly (every 2 weeks): Start Hizentra 1 or 2 weeks after the last IVIg infusion or 1 week after the last weekly SCIg infusion. Administer twice the calculated weekly dose
  • Frequent dosing (2 to 7 times per week): Start Hizentra 1 week after the last IVIg or SCIg infusion. Divide the calculated weekly dose by the desired number of times per week
  • Adjust the dose based on clinical response and serum IgG trough levels

Administering Hizentra therapy

Hizentra should be administered subcutaneously only. Do not administer intravenously. Hizentra can be dosed weekly, using an infusion pump and relatively small needle(s).

CIDP injection site graphic
  • A Hizentra dose may be infused into multiple injection sites. Use up to 8 sites per infusion. More than one infusion device can be used simultaneously. Infusion sites should be at least 2 inches apart. Change the actual site of infusion with each administration
  • Recommended infusion sites include the stomach, thighs, upper arms, or hips
  • SC needles are smaller than IV needles. Depending on a patient's size and weight, a needle as short as 4 mm or as long as 14 mm can be used

Encourage patients to start and stay on therapy

Information and resources are available to help patients manage their ongoing administration of Hizentra.

Managing therapy

Frequently asked questions about Hizentra

Want to know more about Hizentra? See answers to prescribers' frequently asked questions.

See the answers
You are now leaving the current website.

Do you want to continue?

No Yes